A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 30, 2024

Primary Completion Date

December 19, 2032

Study Completion Date

December 19, 2032

Conditions
Smoldering Multiple Myeloma (SMM)
Interventions
DRUG

Linvoseltamab

Administration by intravenous (IV) infusion

Trial Locations (17)

15706

RECRUITING

Hospital Clinico Universitario Santiago de Compostela, Santiago de Compostela

18014

RECRUITING

Hospital Universitario Virgen de las Nieves, Granada

28009

RECRUITING

Hospital General Universitario Gregorio Maranon (HGUGM) - Instituto de Investigacion Sanitaria Gregorio Maranon, Madrid

28027

RECRUITING

Clinica Universidad de Navarra - Madrid, Madrid

28034

RECRUITING

Hospital Universitario Ramon y Cajal, Madrid

28223

RECRUITING

Hospital Universitario Quiron Salud Madrid, Pozuelo de Alarcón

30120

RECRUITING

Hospital Clinico Universitario Virgen De La Arrixaca, El Palmar

31008

RECRUITING

Clinica Universidad de Navarra - Pamplona, Pamplona

33203

RECRUITING

University Hospital of Cabuenes, Gijón

37007

RECRUITING

Hospital Clinico Universitario de Salamanca, Salamanca

39008

RECRUITING

Hospital Universitario Marques de Valdecilla, Santander

46017

RECRUITING

University Hospital Doctor Peset, Valencia

46026

RECRUITING

La Fe University Hospital, Valencia

07198

RECRUITING

Hospital Universitari Son Llatzer, Palma Mallorca

08916

RECRUITING

Hospital Germans Trias i Pujol, Badalona

08036

RECRUITING

Hospital Clinic de Barcelona, Barcelona

08908

RECRUITING

Institut Catala d'Oncologia, Barcelona

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY